One Millionth Biomarker Use

"There are a million reasons for using the Biomarkers Module of Integrity. Here's just one of them..."

The Biomarkers Module of Integrity

The Biomarkers Module of Integrity was designed to support the discovery, qualification and implementation of biomarkers. It brings together all reported uses of biomarkers, in a single place with standardized terminology for indications, biomarker role and level of “validity”. By using the Biomarkers Module, scientists can quickly cut through the wealth of available data and pinpoint the information they need. What’s more, the Biomarkers Module is fully integrated within Thomson Reuters Integrity for additional context and clarity. For more information on how you can benefit from using the Biomarkers Module of Thomson Reuters IntegritySM, click here.

When it first launched in 2008, the Biomarkers Module included 500 biomarkers with 3500 unique uses.

This year, the number of unique uses has passed one million!

To see the millionth unique biomarker use record, click below.

It relates to using the T790M mutation of Epidermal Growth Factor Receptor (EGFR) as a patient stratification biomarker to support clinical development of AZD9291, a new treatment for non-small lung cell carcinoma (NSCLC). This biomarker use was reported at the American Society of Clinical Oncology 2014 Annual Meeting.  

More about the One Millionth Biomarker Use:

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.

AZD9291 is an investigational drug targeted at patients who are resistant to an FDA-approved EGFR tyrosine kinase inhibitor (TKI). In April 2014, AZD9291 was granted Breakthrough Therapy designation by the FDA, for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, whose disease has progressed in spite of prior TKI treatment. The Breakthrough designation allows AstraZeneca to expedite the US development of AZD9291. AstraZeneca plans to begin Phase III trials soon. The study took samples from tumor tissue and circulating tumor DNA from plasma; the results were highly concordant between the two sample types. Using plasma for cancer diagnosis is a less-invasive method of sample collection and can be used for patients who are unable or unwilling to provide tumor tissue. AstraZeneca, in partnership with Roche, is now developing a companion diagnostic kit for AZD9291 based on T790M mutation detection in plasma samples of NSCLC patients.